drugset / Trial / NCT05747534
AT1001 for the Treatment of Long COVID
Phase 2
Active not recruiting
107 enrolled
Massachusetts General Hospital
Boston Children's Hospital, Boston, MA, USA · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and efficacy of Larazotide (AT1001) versus placebo in children and adults 7 to ≤50 years of age who present with symptoms of Long COVID in the presence of SARS-CoV-2 antigenemia. AT1001 (n=100) or placebo (n=50) will be administered orally four times a day (QID) for 21 days.
Timeline
- Start
- 2023-05-31
- Primary completion
- 2026-06-05
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Larazotide | Peptide | 250 ug | Oral |
| Subject | Larazotide | Peptide | 500 ug | Oral |